Treating dyslipidemia in the high-risk patient.
Clinical trials demonstrate that cardiovascular event rates diminish as low-density lipoprotein (LDL)-cholesterol and apolipoprotein B-containing particles are lowered with statin treatment. The relationship between LDL-cholesterol and cardiovascular events seems to be linear, with no lowest threshold. While LDL-cholesterol remains the primary target for coronary heart disease prevention, non-HDL-cholesterol is an important secondary target in patients with mixed dyslipidemia.
Lipid Metabolism and Atherosclerosis Clinic, Baylor College of Medicine, Houston, TX, USA. jones@bcm.tmc.edu
Peter H
PH
Jones
D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control; D050171:Dyslipidemias / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents